File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice

TitleThe fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice
Authors
Issue Date2003
PublisherAmerican Society for Clinical Investigation. The Journal's web site is located at http://www.jci.org
Citation
Journal Of Clinical Investigation, 2003, v. 112 n. 1, p. 91-100 How to Cite?
AbstractAdiponectin has recently been shown to be a promising candidate for the treatment of obesity-associated metabolic syndromes. Replenishment of recombinant adiponectin in mice can decrease hyperglycemia, reverse insulin resistance, and cause sustained weight loss without affecting food intake. Here we report its potential roles in alcoholic and nonalcoholic fatty liver diseases in mice. Circulating concentrations of adiponectin decreased significantly following chronic consumption of high-fat ethanol-containing food. Delivery of recombinant adiponectin into these mice dramatically alleviated hepatomegaly and steatosis (fatty liver) and also significantly attenuated inflammation and the elevated levels of serum alanine aminotransferase. These therapeutic effects resulted partly from the ability of adiponectin to increase carnitine palmitoyltransferase I activity and enhance hepatic fatty acid oxidation, while it decreased the activities of two key enzymes involved in fatty acid synthesis, including acetyl-CoA carboxylase and fatty acid synthase. Furthermore, adiponectin treatment could suppress the hepatic production of TNF-α and plasma concentrations of this proinflammatory cytokine. Adiponectin was also effective in ameliorating hepatomegaly, steatosis, and alanine aminotransferase abnormality associated with nonalcoholic obese, ob/ob mice. These results demonstrate a novel mechanism of adiponectin action and suggest a potential clinical application of adiponectin and its agonists in the treatment of liver diseases.
Persistent Identifierhttp://hdl.handle.net/10722/42411
ISSN
2015 Impact Factor: 12.575
2015 SCImago Journal Rankings: 8.764
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorXu, Aen_HK
dc.contributor.authorWang, Yen_HK
dc.contributor.authorKeshaw, Hen_HK
dc.contributor.authorXu, LYen_HK
dc.contributor.authorLam, KSLen_HK
dc.contributor.authorCooper, GJSen_HK
dc.date.accessioned2007-01-29T08:49:19Z-
dc.date.available2007-01-29T08:49:19Z-
dc.date.issued2003en_HK
dc.identifier.citationJournal Of Clinical Investigation, 2003, v. 112 n. 1, p. 91-100en_HK
dc.identifier.issn0021-9738en_HK
dc.identifier.urihttp://hdl.handle.net/10722/42411-
dc.description.abstractAdiponectin has recently been shown to be a promising candidate for the treatment of obesity-associated metabolic syndromes. Replenishment of recombinant adiponectin in mice can decrease hyperglycemia, reverse insulin resistance, and cause sustained weight loss without affecting food intake. Here we report its potential roles in alcoholic and nonalcoholic fatty liver diseases in mice. Circulating concentrations of adiponectin decreased significantly following chronic consumption of high-fat ethanol-containing food. Delivery of recombinant adiponectin into these mice dramatically alleviated hepatomegaly and steatosis (fatty liver) and also significantly attenuated inflammation and the elevated levels of serum alanine aminotransferase. These therapeutic effects resulted partly from the ability of adiponectin to increase carnitine palmitoyltransferase I activity and enhance hepatic fatty acid oxidation, while it decreased the activities of two key enzymes involved in fatty acid synthesis, including acetyl-CoA carboxylase and fatty acid synthase. Furthermore, adiponectin treatment could suppress the hepatic production of TNF-α and plasma concentrations of this proinflammatory cytokine. Adiponectin was also effective in ameliorating hepatomegaly, steatosis, and alanine aminotransferase abnormality associated with nonalcoholic obese, ob/ob mice. These results demonstrate a novel mechanism of adiponectin action and suggest a potential clinical application of adiponectin and its agonists in the treatment of liver diseases.en_HK
dc.format.extent360783 bytes-
dc.format.extent25088 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypeapplication/msword-
dc.languageengen_HK
dc.publisherAmerican Society for Clinical Investigation. The Journal's web site is located at http://www.jci.orgen_HK
dc.relation.ispartofJournal of Clinical Investigationen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshFatty acids - metabolismen_HK
dc.subject.meshFatty liver - drug therapyen_HK
dc.subject.meshIntercellular signaling peptides and proteinsen_HK
dc.subject.meshMice, inbred c57blen_HK
dc.subject.meshObesity, morbid - blooden_HK
dc.titleThe fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in miceen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0021-9738&volume=112&issue=1&spage=91&epage=100&date=2003&atitle=The+fat-derived+hormone+adiponectin+alleviates+alcoholic+and+nonalcoholic+fatty+liver+diseases+in+miceen_HK
dc.identifier.emailXu, A: amxu@hkucc.hku.hken_HK
dc.identifier.emailWang, Y: yuwanghk@hku.hken_HK
dc.identifier.emailLam, KSL: ksllam@hku.hken_HK
dc.identifier.authorityXu, A=rp00485en_HK
dc.identifier.authorityWang, Y=rp00239en_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1172/JCI200317797en_HK
dc.identifier.pmid12840063en_HK
dc.identifier.pmcidPMC162288-
dc.identifier.scopuseid_2-s2.0-0041302377en_HK
dc.identifier.hkuros114923-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0041302377&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume112en_HK
dc.identifier.issue1en_HK
dc.identifier.spage91en_HK
dc.identifier.epage100en_HK
dc.identifier.isiWOS:000183926700015-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridXu, A=7202655409en_HK
dc.identifier.scopusauthoridWang, Y=34973733700en_HK
dc.identifier.scopusauthoridKeshaw, H=16637431800en_HK
dc.identifier.scopusauthoridXu, LY=8687795700en_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK
dc.identifier.scopusauthoridCooper, GJS=7402355946en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats